| Literature DB >> 25276202 |
Abbas Azadmehr1, Amir Ziaee2, Laleh Ghanei2, Hassan Fallah Huseini3, Reza Hajiaghaee4, Bahareh Tavakoli-Far5, Gholamreza Kordafshari6.
Abstract
Diabetes is a common metabolic disease in the world that has many adverse effects. Olibanum gum resin (from trees of the genus Boswellia) has traditionally been used in the treatment of various diseases such as diabetes. The aim of this study was the comparison of Olibanum gum resin effect with placebo on the treatment of type 2 diabetes. Inclusion criteria was diabetic patients with fasting blood sugar (FBS) =140-200 mg/dL. This study has been designed as double-blined clinical trial on 71 patients with type 2 diabetes and the patients randomly were divided to interventional and placebo groups. The patients on standard anti-diabetic therapy (metformin) treated with Olibanum gum resin (400 mg caps) and placebo tow times per day for 12 weeks, respectively. At the end of the twelfth week, the FBS, HbA1c, Insulin, total Cholesterol (Chol), LDL, Triglyceride (TG), HDL and other parameters were measured. The Olibanum gum resin lowered the FBS, HbA1c, Insulin, Chol, LDL and TG levels significantly (p < 0.001, p < 0.001, p <0.001, p = 0.003, p < 0.001 and p < 0.001, respectively) without any significant effects on the other blood lipid levels and liver/kidney function tests (p > 0.05) compared with the placebo at the endpoint. Moreover, this plant showed anti-oxidant effect and also no adverse effects were reported. The results suggest that Olibanum gum resin could be used as a safe anti-oxidant, anti-hyperglycemic and anti-hyperlipidemic agent for type 2 diabetic patients.Entities:
Keywords: Diabetes; Hyperglycemia; Hyperlipidemia; Olibanum gum resin; Patients
Year: 2014 PMID: 25276202 PMCID: PMC4177622
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1The consort flowchart describing the progress of the patients through the trial
The demographic data of the subjects who finished the trail. The data are given as mean ± SD.
|
|
| |
|---|---|---|
|
|
| |
| Age (year) | 51.4 ± 12.2 | 50.7 ± 14.4 |
| Gender | 23 male, 14 female | 19 male, 15 female |
| Duration of Type 2 diabetes (years) | 5.8 ± 4.7 | 5.6 ± 3.9 |
| Body mass index (kg/m2) | 29.2 ± 5.8 | 28.3 ± 5.4 |
Phytochemical results of the Gum olibanum resin
|
|
|
|
|
|---|---|---|---|
| + | Vanillin sulfuric acid |
| Terpenoids and phenylpropanoids |
| + | Ferric chloride | Chloroform: ethyl-acetate: formic acid (5:4:1) | Phenolic compounds |
| + | Natural product reagent | Ethyl acetate: methanol: water (100:13.5:10) | Flavonoides |
The participant data in the Gum olibanum resin powder (1) group (n=37) and the placebo (2) group (n=34) at baseline and after 12 weeks of the trial.
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
| FBS (mg/dL) | 1 | 156.8 (10.5) | 0.739 | 1 | 129.2 (9.1) | <0.001* | 1 | 17.6 ↓ |
| 2 | 156.1 (9.2) | 2 | 153.9 (7.5) | 2 | 1.4 ↓ | |||
| HbA1c (%) | 1 | 7.26 | 0.203 | 1 | 6.9 (0.38) | <0.001* | 1 | 4.95 ↓ |
| 2 | 7.42 ( 0.44) | 2 | 7.41 (0.2) | 2 | 0.13 ↓ | |||
| Insulin (UI/L) | 1 | 12.3 ( 6.3) | 0.272 | 1 | 9.26 (2.7) | <0.001* | 1 | 24.7 ↓ |
| 2 | 10.84 ( 2.78) | 2 | 10.1 (1.95) | 2 | 6.8 ↓ | |||
| Chol (mg/dL) | 1 | 173.2 (27.1) | 0.878 | 1 | 162.3 (27.5) | 0.003* | 1 | 6.3 ↓ |
| 2 | 172.4 ( 42.5) | 2 | 175.7 ( 29.1) | 2 | 1.92 ↑ | |||
| LDL (mg/dL) | 1 | 101.7 (24.8) | 0.6 | 1 | 88.4 (23.3) | <0.001* | 1 | 13.1 ↓ |
| 2 | 98.6 (25.02) | 2 | 97.3 (23.1) | 2 | 1.4 ↓ | |||
| TG (mg/dL) | 1 | 176.1 (44.5) | 0.246 | 1 | 164.6 ( 38.4) | <0.001* | 1 | 6.53 ↓ |
| 2 | 171.1 ( 36.8) | 2 | 172.5 ( 33.3) | 2 | 0.81 ↑ | |||
P< 0.05 was considered as statistically significant.
Figure 2Box plot of decreases (before intervention – after intervention) in the fasting blood sugar (FBS) levels (mg/dL) of the Olibanum gum resin and placebo groups.
Figure 7Box plot of decreases (before intervention – after intervention) in the blood LDL levels (mg/dL) of the Olibanum gum resin and placebo groups